Kinase inhibitors for alopecia
Customize your policy alerts
Sign up for allcareadvantage Policy 121.1 alerts
Get alerted when Policy 121.1 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization and coverage criteria for kinase inhibitor medications (baricitinib/Olumiant and ritlecitinib/Litfulo) used to treat severe alopecia areata for AllCare Advantage members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Kinase Inhibitors
Initial Therapy
Covered when ALL of the following are met
Continuation Therapy / Renewal
Renewal criteria
Approvals for renewal are up to 12 months.
This policy references alternative diagnoses per UMCCOMED076 for situations where the criteria for severe alopecia areata do not apply. If the submitted documentation indicates a condition other than severe alopecia areata, refer to UMCCOMED076 for the appropriate diagnostic classification and coverage pathway.
Do not approve therapy when the member does not meet the policy’s required criteria. Specifically, requests must meet the FDA-approved age and dosing indications for the requested agent; if the patient does not meet these age/dosing requirements, do not approve. For members ≤20 years of age, refer the case to a medical director for clinical necessity review as noted in the policy. Renewal requests must show that the member met the initial criteria and that there is documentation demonstrating successful treatment response; renewals without adequate documentation should be denied.
Initial Therapy Criteria
Initial Therapy
Initial approval criteria and limits
Quantity limit: 1 per day.
Continuation / Renewal Criteria
Renewal
Renewal
If member did not meet initial criteria or documentation of successful treatment is not provided, deny renewal.
Provider Actions and Requirements
Prior authorization required; approval durations
Prior authorization is required for kinase inhibitors for alopecia. Initial approvals are granted for up to 6 months; renewals may be approved for up to 12 months. Requests must demonstrate the member meets the policy criteria (diagnosis of severe alopecia areata, FDA age/dosing indications) and that the prescription is by or in consultation with a specialist.
- Initial approval length: up to 6 months.
- Renewal approval length: up to 12 months.
- Requests must show diagnosis, meet FDA age/dosing indications, and be prescribed by or in consultation with a specialist.
No step therapy sequence described
This policy does not specify a step therapy sequence; no step requirements are described in the document.
Submit documentation of diagnosis and treatment response
Provide sufficient documentation to support a diagnosis of severe alopecia areata for initial requests and documentation of successful treatment response for renewals.
- Initial requests: documentation supporting diagnosis of severe alopecia areata.
- Renewals: documentation demonstrating the patient has experienced successful treatment.
Denial triggers for initial requests and renewals
Deny initial requests that do not meet the policy criteria; deny renewals if documentation does not demonstrate successful treatment. Patients who do not meet FDA age/dosing indications or are ≤20 years of age may require MD review and could be denied pending review.
- Denial at initial review if required criteria (diagnosis, age/dosing, specialist prescriber) are not met.
- Denial at renewal if documentation does not show successful treatment.
- Members ≤20 years old may be referred for MD review and potentially denied pending that review.
Quantity Limits and Class
Definitions
Background
Kinase inhibitors referenced in this policy act on intracellular signaling pathways implicated in alopecia areata, with the agents included targeting relevant kinases to reduce immune-mediated hair loss. Dosing guidance in the policy mirrors product recommendations: baricitinib (Olumiant) is used in adults with an initial 2 mg once daily dose with the option to increase to 4 mg once daily for inadequate response, and ritlecitinib (Litfulo) is dosed at 50 mg once daily. The policy covers baricitinib for members ≥18 years and ritlecitinib for members ≥12 years consistent with the FDA age indications cited.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.